## Abstract This report describes the synthesis of the ^13^C‐enriched and ^14^C‐labelled title compound starting from isotopically labelled isovaleraldehyde.
Syntheses of 14C-labelled monoacidic metabolites of dithiopyr
✍ Scribed by Mohammad E. Mehrsheikh; Lane A. Clizbe; Harbhajan Singh; Wr Purdum
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 210 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0022-2135
No coin nor oath required. For personal study only.
✦ Synopsis
Convenient methods for the selective hydrolysis of the thioester groups of dithiopyr to the corresponding carboxylic acid are described. 2-@ifluoromethyl)-4-(2-methylpropyl)-5-[ (methylthio)carbnyl] -6-(trifluoromethyl)-3-pyridine-4-~~C-carboxylic acid (2) was obtained by simple potassium hydroxide hydrolysis of 14C-labelled dithiopyr. A more involve strategy was necessary for the preparation of the isomeric carboxylic acid 6-(difluoromethyl)-4-(2-methylpropyl)-5-[(methylthio) carbonyl]-2-(trifluoromethyl)-3-pyridine-4-14Ccarboxylic acid Q)
📜 SIMILAR VOLUMES
## Abstract The synthesis of Asaley labelled with ^14^C in the mustard (Asaley‐must‐^14^C) or the leucine (Asaley‐leu‐^14^C) moiety is described. In the former, ethyl pamino‐N^α^‐acetyl‐DL‐phenylalanyl‐L‐leucinate was reacted with ethylene oxide(U)‐^14^C to give the bis(hydroxyethyl)amino analogue,
Two syntheses o f r a d i o l a b e l l e d p r i z i d l l o l d i h y d r o c h l o r l d e (DL)3-[2-(3-t-butylamino -2-hydroxypropoxy)phenyl]-6-hydrazinop y r i d a z l n e d i h y d r o c h l o r i d e ) a r e described. 1. A t e n stage synthesis (Scheme 1) which gave 14 [3,6y i e l d o f 0.91%
## Abstract For studies of pharmacokinetics and drug metabolism of the new orally active, selective phosphodiesterase type V (PDE V) inhibitor vardenafil (Levitra^®^), the ^14^C‐labelled version was synthesised. Starting from the cyanation of 2‐iodophenol with K^14^CN, an 8‐step synthesis led to tw
Nexavar TM , Sorafenib tosylate (BAY 43-9006 tosylate) is a potent small molecule Raf kinase inhibitor for the treatment of hyperproliferative disorders such as cancer. Both radiolabeled and stable isotope labeled compounds were required for drug absorption, distribution, metabolism and excretion (A
## 4-[4-(4-Chlorophen y l ) -4-hydroxypiperidinol -4 ' -f l u o r o b u t y r op h e n o n e ( h a l o p e r i d o l ) ( I ) and 4'-fluoro-4-[4-hydroxy-4-(3-trif 1 u o r o m e t h y l p h e n y l ) p i p e r i d i n o l b u t y r o p h e n o n e ( t r i f 1 u p e r i d o f ) (11) , n e u r o l e p t